Measurement of Serum Levels of Macrophage Inhibitory Cytokine 1 Combined with Prostate-Specific Antigen Improves Prostate Cancer Diagnosis
Purpose: Current serum testing for the detection of prostate cancer (PCa) lacks specificity. On diagnosis, the optimal therapeutic pathway is not clear and tools for adequate risk assessment of localized PCa progression are not available. This leads to a significant number of men having unnecessary...
Gespeichert in:
| Veröffentlicht in: | Clinical cancer research 2006-01, Vol.12 (1), p.89-96 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 96 |
|---|---|
| container_issue | 1 |
| container_start_page | 89 |
| container_title | Clinical cancer research |
| container_volume | 12 |
| creator | BROWN, David A STEPHAN, Carsten RUSSELL, Pamela J GILES, Graham G BREIT, Samuel N WARD, Robyn L LAW, Mathew HUNTER, Mark BAUSKIN, Asne R AMIN, Janaki JUNG, Klaus DIAMANDIS, Eleftherios P HAMPTON, Garret M |
| description | Purpose: Current serum testing for the detection of prostate cancer (PCa) lacks specificity. On diagnosis, the optimal therapeutic
pathway is not clear and tools for adequate risk assessment of localized PCa progression are not available. This leads to
a significant number of men having unnecessary diagnostic biopsies and surgery. A search for novel tumor markers identified
macrophage inhibitory cytokine 1 (MIC-1) as a potentially useful marker. Follow-up studies revealed MIC-1 overexpression in
local and metastatic PCa whereas peritumoral interstitial staining for MIC-1 identified lower-grade tumors destined for recurrence.
Consequently, we sought to assess serum MIC-1 measurement as a diagnostic tool.
Experimental Design: Using immunoassay determination of serum MIC-1 concentration in 1,000 men, 538 of whom had PCa, we defined the relationship
of MIC-1 to disease variables. A diagnostic algorithm ( MIC-PSA score) based on serum levels of MIC-1, total serum prostate-specific antigen, and percentage of free prostate-specific antigen
was developed.
Results: Serum MIC-1 was found to be an independent predictor of the presence of PCa and tumors with a Gleason sum ≥7. We validated
the MIC-PSA score in a separate population and showed an improved specificity for diagnostic blood testing for PCa over percentage of
free prostate-specific antigen, potentially reducing unnecessary biopsies by 27%.
Conclusions: Serum MIC-1 is an independent marker of the presence of PCa and tumors with a Gleason sum of ≥7. The use of serum MIC-1 significantly
increases diagnostic specificity and may be a future tool in the management of PCa. |
| doi_str_mv | 10.1158/1078-0432.CCR-05-1331 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67607901</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17466282</sourcerecordid><originalsourceid>FETCH-LOGICAL-c399t-59175b6599cdae82c4a26a69d663724c981e7e6f9fda3c63ecde2d3eb07ff0c63</originalsourceid><addsrcrecordid>eNqFkU1v1DAQhiMEoqXwE0C-wC3FY8d2fKxSPlbaCkThbDnOZGPIx2InrfYv8Ktx6MIeOXlsPeMZvU-WvQR6CSDKt0BVmdOCs8uq-pJTkQPn8Cg7ByFUzpkUj1P9lznLnsX4nVIogBZPszOQXCvK9Hn26wZtXAIOOM5kaskthmUgW7zDPq73G-vCtO_sDslm7Hzt5ykcSHWYpx9-RAKkmoY6VQ2593NHPocpznbG_HaPzrfekatx9jscyWbYh-kO4z-EVHZ0GMi1t7txij4-z560to_44nheZN_ev_tafcy3nz5sqqtt7rjWcy40KFFLobVrLJbMFZZJK3UjJVescLoEVChb3TaWO8nRNcgajjVVbUvTw0X25uHftNDPBeNsBh8d9r0dcVqikUpSpSn8FwRVSMlKlkDxAKasYgzYmn3wgw0HA9SstsxqwqwmTLJlqDCrrdT36jhgqQdsTl1HPQl4fQRsdLZvQ4rMxxOnBAgJ4rRp53fdvQ9o3J9wA0a0wXUGmAFTav4bHXKtIg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17466282</pqid></control><display><type>article</type><title>Measurement of Serum Levels of Macrophage Inhibitory Cytokine 1 Combined with Prostate-Specific Antigen Improves Prostate Cancer Diagnosis</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>BROWN, David A ; STEPHAN, Carsten ; RUSSELL, Pamela J ; GILES, Graham G ; BREIT, Samuel N ; WARD, Robyn L ; LAW, Mathew ; HUNTER, Mark ; BAUSKIN, Asne R ; AMIN, Janaki ; JUNG, Klaus ; DIAMANDIS, Eleftherios P ; HAMPTON, Garret M</creator><creatorcontrib>BROWN, David A ; STEPHAN, Carsten ; RUSSELL, Pamela J ; GILES, Graham G ; BREIT, Samuel N ; WARD, Robyn L ; LAW, Mathew ; HUNTER, Mark ; BAUSKIN, Asne R ; AMIN, Janaki ; JUNG, Klaus ; DIAMANDIS, Eleftherios P ; HAMPTON, Garret M</creatorcontrib><description>Purpose: Current serum testing for the detection of prostate cancer (PCa) lacks specificity. On diagnosis, the optimal therapeutic
pathway is not clear and tools for adequate risk assessment of localized PCa progression are not available. This leads to
a significant number of men having unnecessary diagnostic biopsies and surgery. A search for novel tumor markers identified
macrophage inhibitory cytokine 1 (MIC-1) as a potentially useful marker. Follow-up studies revealed MIC-1 overexpression in
local and metastatic PCa whereas peritumoral interstitial staining for MIC-1 identified lower-grade tumors destined for recurrence.
Consequently, we sought to assess serum MIC-1 measurement as a diagnostic tool.
Experimental Design: Using immunoassay determination of serum MIC-1 concentration in 1,000 men, 538 of whom had PCa, we defined the relationship
of MIC-1 to disease variables. A diagnostic algorithm ( MIC-PSA score) based on serum levels of MIC-1, total serum prostate-specific antigen, and percentage of free prostate-specific antigen
was developed.
Results: Serum MIC-1 was found to be an independent predictor of the presence of PCa and tumors with a Gleason sum ≥7. We validated
the MIC-PSA score in a separate population and showed an improved specificity for diagnostic blood testing for PCa over percentage of
free prostate-specific antigen, potentially reducing unnecessary biopsies by 27%.
Conclusions: Serum MIC-1 is an independent marker of the presence of PCa and tumors with a Gleason sum of ≥7. The use of serum MIC-1 significantly
increases diagnostic specificity and may be a future tool in the management of PCa.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>DOI: 10.1158/1078-0432.CCR-05-1331</identifier><identifier>PMID: 16397029</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Antineoplastic agents ; Biological and medical sciences ; Biomarkers, Tumor - blood ; Cytokines - blood ; Diagnosis ; Growth Differentiation Factor 15 ; Humans ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Prostate cancer ; Prostate-Specific Antigen - blood ; Prostatic Neoplasms - blood ; Retrospective Studies ; Sensitivity and Specificity ; Serum MIC-1 ; transforming growth factor-β superfamily</subject><ispartof>Clinical cancer research, 2006-01, Vol.12 (1), p.89-96</ispartof><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c399t-59175b6599cdae82c4a26a69d663724c981e7e6f9fda3c63ecde2d3eb07ff0c63</citedby><cites>FETCH-LOGICAL-c399t-59175b6599cdae82c4a26a69d663724c981e7e6f9fda3c63ecde2d3eb07ff0c63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3343,4010,27900,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17515615$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16397029$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BROWN, David A</creatorcontrib><creatorcontrib>STEPHAN, Carsten</creatorcontrib><creatorcontrib>RUSSELL, Pamela J</creatorcontrib><creatorcontrib>GILES, Graham G</creatorcontrib><creatorcontrib>BREIT, Samuel N</creatorcontrib><creatorcontrib>WARD, Robyn L</creatorcontrib><creatorcontrib>LAW, Mathew</creatorcontrib><creatorcontrib>HUNTER, Mark</creatorcontrib><creatorcontrib>BAUSKIN, Asne R</creatorcontrib><creatorcontrib>AMIN, Janaki</creatorcontrib><creatorcontrib>JUNG, Klaus</creatorcontrib><creatorcontrib>DIAMANDIS, Eleftherios P</creatorcontrib><creatorcontrib>HAMPTON, Garret M</creatorcontrib><title>Measurement of Serum Levels of Macrophage Inhibitory Cytokine 1 Combined with Prostate-Specific Antigen Improves Prostate Cancer Diagnosis</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>Purpose: Current serum testing for the detection of prostate cancer (PCa) lacks specificity. On diagnosis, the optimal therapeutic
pathway is not clear and tools for adequate risk assessment of localized PCa progression are not available. This leads to
a significant number of men having unnecessary diagnostic biopsies and surgery. A search for novel tumor markers identified
macrophage inhibitory cytokine 1 (MIC-1) as a potentially useful marker. Follow-up studies revealed MIC-1 overexpression in
local and metastatic PCa whereas peritumoral interstitial staining for MIC-1 identified lower-grade tumors destined for recurrence.
Consequently, we sought to assess serum MIC-1 measurement as a diagnostic tool.
Experimental Design: Using immunoassay determination of serum MIC-1 concentration in 1,000 men, 538 of whom had PCa, we defined the relationship
of MIC-1 to disease variables. A diagnostic algorithm ( MIC-PSA score) based on serum levels of MIC-1, total serum prostate-specific antigen, and percentage of free prostate-specific antigen
was developed.
Results: Serum MIC-1 was found to be an independent predictor of the presence of PCa and tumors with a Gleason sum ≥7. We validated
the MIC-PSA score in a separate population and showed an improved specificity for diagnostic blood testing for PCa over percentage of
free prostate-specific antigen, potentially reducing unnecessary biopsies by 27%.
Conclusions: Serum MIC-1 is an independent marker of the presence of PCa and tumors with a Gleason sum of ≥7. The use of serum MIC-1 significantly
increases diagnostic specificity and may be a future tool in the management of PCa.</description><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - blood</subject><subject>Cytokines - blood</subject><subject>Diagnosis</subject><subject>Growth Differentiation Factor 15</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Prostate cancer</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatic Neoplasms - blood</subject><subject>Retrospective Studies</subject><subject>Sensitivity and Specificity</subject><subject>Serum MIC-1</subject><subject>transforming growth factor-β superfamily</subject><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU1v1DAQhiMEoqXwE0C-wC3FY8d2fKxSPlbaCkThbDnOZGPIx2InrfYv8Ktx6MIeOXlsPeMZvU-WvQR6CSDKt0BVmdOCs8uq-pJTkQPn8Cg7ByFUzpkUj1P9lznLnsX4nVIogBZPszOQXCvK9Hn26wZtXAIOOM5kaskthmUgW7zDPq73G-vCtO_sDslm7Hzt5ykcSHWYpx9-RAKkmoY6VQ2593NHPocpznbG_HaPzrfekatx9jscyWbYh-kO4z-EVHZ0GMi1t7txij4-z560to_44nheZN_ev_tafcy3nz5sqqtt7rjWcy40KFFLobVrLJbMFZZJK3UjJVescLoEVChb3TaWO8nRNcgajjVVbUvTw0X25uHftNDPBeNsBh8d9r0dcVqikUpSpSn8FwRVSMlKlkDxAKasYgzYmn3wgw0HA9SstsxqwqwmTLJlqDCrrdT36jhgqQdsTl1HPQl4fQRsdLZvQ4rMxxOnBAgJ4rRp53fdvQ9o3J9wA0a0wXUGmAFTav4bHXKtIg</recordid><startdate>20060101</startdate><enddate>20060101</enddate><creator>BROWN, David A</creator><creator>STEPHAN, Carsten</creator><creator>RUSSELL, Pamela J</creator><creator>GILES, Graham G</creator><creator>BREIT, Samuel N</creator><creator>WARD, Robyn L</creator><creator>LAW, Mathew</creator><creator>HUNTER, Mark</creator><creator>BAUSKIN, Asne R</creator><creator>AMIN, Janaki</creator><creator>JUNG, Klaus</creator><creator>DIAMANDIS, Eleftherios P</creator><creator>HAMPTON, Garret M</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20060101</creationdate><title>Measurement of Serum Levels of Macrophage Inhibitory Cytokine 1 Combined with Prostate-Specific Antigen Improves Prostate Cancer Diagnosis</title><author>BROWN, David A ; STEPHAN, Carsten ; RUSSELL, Pamela J ; GILES, Graham G ; BREIT, Samuel N ; WARD, Robyn L ; LAW, Mathew ; HUNTER, Mark ; BAUSKIN, Asne R ; AMIN, Janaki ; JUNG, Klaus ; DIAMANDIS, Eleftherios P ; HAMPTON, Garret M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c399t-59175b6599cdae82c4a26a69d663724c981e7e6f9fda3c63ecde2d3eb07ff0c63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - blood</topic><topic>Cytokines - blood</topic><topic>Diagnosis</topic><topic>Growth Differentiation Factor 15</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Prostate cancer</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatic Neoplasms - blood</topic><topic>Retrospective Studies</topic><topic>Sensitivity and Specificity</topic><topic>Serum MIC-1</topic><topic>transforming growth factor-β superfamily</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BROWN, David A</creatorcontrib><creatorcontrib>STEPHAN, Carsten</creatorcontrib><creatorcontrib>RUSSELL, Pamela J</creatorcontrib><creatorcontrib>GILES, Graham G</creatorcontrib><creatorcontrib>BREIT, Samuel N</creatorcontrib><creatorcontrib>WARD, Robyn L</creatorcontrib><creatorcontrib>LAW, Mathew</creatorcontrib><creatorcontrib>HUNTER, Mark</creatorcontrib><creatorcontrib>BAUSKIN, Asne R</creatorcontrib><creatorcontrib>AMIN, Janaki</creatorcontrib><creatorcontrib>JUNG, Klaus</creatorcontrib><creatorcontrib>DIAMANDIS, Eleftherios P</creatorcontrib><creatorcontrib>HAMPTON, Garret M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BROWN, David A</au><au>STEPHAN, Carsten</au><au>RUSSELL, Pamela J</au><au>GILES, Graham G</au><au>BREIT, Samuel N</au><au>WARD, Robyn L</au><au>LAW, Mathew</au><au>HUNTER, Mark</au><au>BAUSKIN, Asne R</au><au>AMIN, Janaki</au><au>JUNG, Klaus</au><au>DIAMANDIS, Eleftherios P</au><au>HAMPTON, Garret M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Measurement of Serum Levels of Macrophage Inhibitory Cytokine 1 Combined with Prostate-Specific Antigen Improves Prostate Cancer Diagnosis</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>2006-01-01</date><risdate>2006</risdate><volume>12</volume><issue>1</issue><spage>89</spage><epage>96</epage><pages>89-96</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><abstract>Purpose: Current serum testing for the detection of prostate cancer (PCa) lacks specificity. On diagnosis, the optimal therapeutic
pathway is not clear and tools for adequate risk assessment of localized PCa progression are not available. This leads to
a significant number of men having unnecessary diagnostic biopsies and surgery. A search for novel tumor markers identified
macrophage inhibitory cytokine 1 (MIC-1) as a potentially useful marker. Follow-up studies revealed MIC-1 overexpression in
local and metastatic PCa whereas peritumoral interstitial staining for MIC-1 identified lower-grade tumors destined for recurrence.
Consequently, we sought to assess serum MIC-1 measurement as a diagnostic tool.
Experimental Design: Using immunoassay determination of serum MIC-1 concentration in 1,000 men, 538 of whom had PCa, we defined the relationship
of MIC-1 to disease variables. A diagnostic algorithm ( MIC-PSA score) based on serum levels of MIC-1, total serum prostate-specific antigen, and percentage of free prostate-specific antigen
was developed.
Results: Serum MIC-1 was found to be an independent predictor of the presence of PCa and tumors with a Gleason sum ≥7. We validated
the MIC-PSA score in a separate population and showed an improved specificity for diagnostic blood testing for PCa over percentage of
free prostate-specific antigen, potentially reducing unnecessary biopsies by 27%.
Conclusions: Serum MIC-1 is an independent marker of the presence of PCa and tumors with a Gleason sum of ≥7. The use of serum MIC-1 significantly
increases diagnostic specificity and may be a future tool in the management of PCa.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>16397029</pmid><doi>10.1158/1078-0432.CCR-05-1331</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-0432 |
| ispartof | Clinical cancer research, 2006-01, Vol.12 (1), p.89-96 |
| issn | 1078-0432 1557-3265 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67607901 |
| source | MEDLINE; American Association for Cancer Research; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Antineoplastic agents Biological and medical sciences Biomarkers, Tumor - blood Cytokines - blood Diagnosis Growth Differentiation Factor 15 Humans Male Medical sciences Middle Aged Pharmacology. Drug treatments Prostate cancer Prostate-Specific Antigen - blood Prostatic Neoplasms - blood Retrospective Studies Sensitivity and Specificity Serum MIC-1 transforming growth factor-β superfamily |
| title | Measurement of Serum Levels of Macrophage Inhibitory Cytokine 1 Combined with Prostate-Specific Antigen Improves Prostate Cancer Diagnosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-16T07%3A36%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Measurement%20of%20Serum%20Levels%20of%20Macrophage%20Inhibitory%20Cytokine%201%20Combined%20with%20Prostate-Specific%20Antigen%20Improves%20Prostate%20Cancer%20Diagnosis&rft.jtitle=Clinical%20cancer%20research&rft.au=BROWN,%20David%20A&rft.date=2006-01-01&rft.volume=12&rft.issue=1&rft.spage=89&rft.epage=96&rft.pages=89-96&rft.issn=1078-0432&rft.eissn=1557-3265&rft_id=info:doi/10.1158/1078-0432.CCR-05-1331&rft_dat=%3Cproquest_cross%3E17466282%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17466282&rft_id=info:pmid/16397029&rfr_iscdi=true |